Response and resistance factor candidates to HER2 targeted therapy in gastric cancer (GC)

被引：0
|
作者：
Lordick, F. [1 ]
Haffner, I. [1 ]
Luber, B. [2 ]
Maier, D. [3 ]
Kretzschmar, A. [4 ]
von Weikersthal, L. Fischer [5 ]
Riera-Knorrenschild, J. [6 ]
Ahlborn, M. [7 ]
Schierle, K. [8 ]
Wittekind, C. [8 ]
机构：
[1] Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, Germany
[2] Tech Univ Munich, Munich, Germany
[3] Biomax Informat AG, Planegg, Germany
[4] MVZ Mitte Onkol Schwerpunktpraxis, Leipzig, Germany
[5] Gesundheitszentrum St Marien GmbH, Dept Oncol, Amberg, Germany
[6] Univ Klinikum Giessen & Marburg, Marburg, Germany
[7] Klinikum Braunschweig, Braunschweig, Germany
[8] Univ Hosp Leipzig, Pathol, Leipzig, Germany
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-005
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [41] Alternative targeted therapy for early Her2 positive breast cancer
    Harvey, Sandra L.
    Khasraw, Mustafa
    GLAND SURGERY, 2013, 2 (01) : 42 - 45
  • [42] HER2 Testing in Gastric Cancer
    Albarello, Luca
    Pecciarini, Lorenza
    Doglioni, Claudio
    ADVANCES IN ANATOMIC PATHOLOGY, 2011, 18 (01) : 53 - 59
  • [43] HER2 in focus—gastric cancer
    Aysegül Ilhan-Mutlu
    memo - Magazine of European Medical Oncology, 2023, 16 : 217 - 217
  • [44] Her2 testing in gastric cancer
    Rueschoff, J.
    Nagelmeier, I.
    Baretton, G.
    Dietel, M.
    Hoefler, H.
    Schildhaus, H. U.
    Buettner, R.
    Schlake, W.
    Stoss, O.
    Kreipe, H. H.
    PATHOLOGE, 2010, 31 (03): : 208 - +
  • [45] SERUM HER2 IN GASTRIC CANCER
    Saito, M.
    Kaneto, H.
    Okuda, H.
    Kodaira, J.
    Hagiwara, T.
    Kozawa, H.
    Yoshimoto, M.
    Yamashita, K.
    Arimura, Y.
    Shinomura, Y.
    ANNALS OF ONCOLOGY, 2013, 24 : 33 - 33
  • [46] PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
    McDermott, Martina S. J.
    Browne, Brigid C.
    Conlon, Neil T.
    O'Brien, Neil A.
    Slamon, Dennis J.
    Henry, Michael
    Meleady, Paula
    Clynes, Martin
    Dowling, Paul
    Crown, John
    O'Donovan, Norma
    MOLECULAR CANCER, 2014, 13
  • [47] PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
    Martina S J McDermott
    Brigid C Browne
    Neil T Conlon
    Neil A O’Brien
    Dennis J Slamon
    Michael Henry
    Paula Meleady
    Martin Clynes
    Paul Dowling
    John Crown
    Norma O’Donovan
    Molecular Cancer, 13
  • [48] Heregulin-induced resistance against HER2-targeted therapies in HER2 positive breast and gastric cancer in vitro and in vivo
    Nonagase, Yoshikane
    Yonesaka, Kimio
    Watanabe, Satomi
    Haratani, Koji
    Takahama, Takayuki
    Takegawa, Naoki
    Ueda, Hiroto
    Kawakami, Hisato
    Hayashi, Hidetoshi
    Takeda, Masayuki
    Sakamoto, Haruka
    Tamura, Takao
    Nakagawa, Kazuhiko
    Tsurutani, Junji
    CANCER RESEARCH, 2016, 76
  • [49] Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
    Mou, Exian
    Ji, Juan
    Liu, Shiwei
    Shu, Lan
    Zou, Liqun
    Li, Zhuoxuan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [50] HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
    Xu, Xiaowei
    De Angelis, Carmine
    Burke, Kathleen A.
    Nardone, Agostina
    Hu, Huizhong
    Qin, Lanfang
    Veeraraghavan, Jamunarani
    Sethunath, Vidyalakshmi
    Heiser, Laura M.
    Wang, Nicholas
    Ng, Charlotte K. Y.
    Chen, Edward S.
    Renwick, Alexander
    Wang, Tao
    Nanda, Sarmistha
    Shea, Martin
    Mitchell, Tamika
    Rajendran, Mahitha
    Waters, Ian
    Zabransky, Daniel J.
    Scott, Kenneth L.
    Gutierrez, Carolina
    Nagi, Chandandeep
    Geyer, Felipe C.
    Chamness, Gary C.
    Park, Ben H.
    Shaw, Chad A.
    Hilsenbeck, Susan G.
    Rimawi, Mothaffar F.
    Gray, Joe W.
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Osborne, C. Kent
    Schiff, Rachel
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5123 - 5134
12345